Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males With Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Trial Profile

A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males With Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGT 003 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man
  • Acronyms INSPIRE DUCHENNE
  • Sponsors Solid Biosciences

Most Recent Events

  • 30 Apr 2026 According to Solid Biosciences media release, the data from the trial will be presented at the upcoming 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 2026.
  • 20 Mar 2026 According to Solid Biosciences media release, 41 participants dosed as of March 18, 2026.
  • 11 Mar 2026 According to Solid Biosciences media release, The interim update was delivered in an oral presentation at the 2026 MDA Annual Meeting on March 11, 2026,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top